DOCSLIB.ORG

Cannabis Legal Regulatory Update January

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cannabis Legal Regulatory Update January Allen & Overy | Cannabis Legal & Regulatory Update View this email in your browser Cannabis Legal & Regulatory Update January ­ March 2019 PDF version The A&O view In the last couple of months, the WHO Expert Committee on Drug Dependence (ECDD)’s recommendations on rescheduling cannabis and its derivatives in the international drug conventions have filled the cannabis industry with hope. Removing cannabis from the strictest Schedule IV (also including heroin and cocaine) is a logical – and overdue – step given the well­established medical use of the plant. However, in particular a vote in favour of removing cannabis “extracts and tinctures” from Schedule I (as recommended by the ECDD) may open up new possibilities for the CBD industry, which often faces legal hurdles on this basis given that CBD is not a scheduled substance in itself. We may soon expect approval of the first EU­wide approved cannabis­based medicine (Epidyolex®), and the European Parliament Resolution on the use of cannabis for medical purposes, which clearly recognises its medical use and specifically calls on the EU Commission and Member States for more research and innovation in this respect, will likely make us see more of these in the future. Many EU member states and other countries have recently authorised medical cannabis (e.g. UK) or are in the process of doing so (e.g. France), in order to provide access to patients but simultaneously being aware of the extra source of state income such authorisation represents. These positive recent developments in the medical sphere could nevertheless reinforce the idea of only two categories of cannabis – licit medical use vs. illicit recreational use – without taking into account the broad category of hemp­derived products (e.g. in the paper and construction industry, but also in cosmetics, food supplements, etc.) sold legally throughout Europe. It is more than time that EU authorities clarify their interpretation of the rules with respect to such “well­being” products, but the recent (non­binding) Novel Food Catalogue update – suggesting an overly restrictive rather than tailored approach – will provide the emerging CBD industry with food for thought for at least the months to come… Enjoy the newsletter! CONTENT __1. HIGHLIGHTS __2. LATEST LAWS, REGULATORY GUIDANCE AND ENFORCEMENT ACTIONS ___2.1. Medical Cannabis ___2.2. Well­Being Cannabis ___2.3. Recreational Cannabis __3. SELECTED INDUSTRY AND MARKET NEWS _1. HIGHLIGHTS UNITED NATIONS – WHO Expert Committee on Drug Dependence (ECDD) releases recommendations on rescheduling cannabis and derivatives under International Law On 24 January 2019, the WHO Expert Committee on Drug Dependence (ECDD) published its letter addressed to the Secretary­General of the United Nations summarising the recommendations of its 41st meeting. The ECCD advocates inter alia, for the deletion of cannabis and cannabis resin from Schedule IV and the deletion of extracts and tinctures of cannabis from Schedule I of the Single Convention on Narcotic Drugs (1961). However, the United Nations Commission on Narcotic Drugs (CND) vote, which is required to approve the ECDD recommendations and was originally scheduled on 7 March 2019, has been postponed. The ECDD letter is available here, an extract from the ECDD report here and a related article here EUROPEAN UNION – European Parliament adopts a motion for a resolution calling for more research and innovation regarding medical cannabis On 13 February 2019, the European Parliament adopted a motion for a resolution related to the use of cannabis for medical purposes. The motion clearly recognises the medical use of cannabis and calls for more research and innovation regarding medical cannabis. MEPs also call on the Commission and national authorities to draw a clearer distinction between medical cannabis and other uses of cannabis. The amended draft resolution is available here and the Parliament press release here EUROPEAN UNION – European authorities clarify cannabinoid status under Novel Foods Regulation In January 2019, European authorities updated the Novel Food Catalogue in an attempt to clarify the status of products derived from the Cannabis Sativa L. plant and cannabinoids under the Novel Foods Regulation. The “Cannabis Sativa L” entry was updated, and specifically recognises that certain parts of the plant (e.g. seeds) are not novel. In contrast, the “Cannabidiol (CBD)” entry was deleted and replaced by a more general “cannabinoid” entry, which now states that products containing cannabinoids are considered novel foods. The Novel Foods Regulation is available here and the Novel Food Catalogue here _2. LATEST LAWS, REGULATORY GUIDANCE AND ENFORCEMENT ACTIONS 2.1. MEDICAL CANNABIS ARGENTINA – National Security Ministry approves first cultivation project for medical cannabis On 4 February 2019, the National Security Ministry authorised the first company (in history!) to cultivate cannabis for medical purposes in Argentina by approving the security protocol proposed by Cannabis Avãtara State Society (together with its partner Players Network – Green Leaf Farms International). The resolution is available here (ES) and a related article here BELGIUM – House of Representatives approves motion for resolution in favour of medical cannabis On 27 February 2019, the Belgian House of Representatives’ Health Committee approved the motion for a resolution in favour of cannabis for medical use. The motion aims to create a Cannabis Office (under control of the Belgian State) which would supervise medical cannabis cultivation and trade. It also seeks to enlarge the scope of prescribing cannabis for medical purposes. The motion is available here (FR and NL) and a related article here CYPRUS – Legislators pass a bill authorising medical cannabis under specific conditions On 15 February 2019, legislators adopted an amendment to the Narcotic Drugs and Psychotropic Substances Law which permits, under certain conditions and subject to a specific licence, the cultivation of medical cannabis and regulates its import/export, production and distribution, as well as its use for scientific research. A related article is available here DENMARK – Denmark implements measures to allow reimbursement and export of medical cannabis On 1 January, 2019, a special reimbursement scheme for medical cannabis entered into force which allows Danish citizens to obtain reimbursement for medical cannabis that has been prescribed in the context of the four­year pilot programme. This reimbursement scheme will apply retroactively to purchases made in 2018. The explanatory note of the Danish Medicines Agency is available here On the same date, an executive order of the Danish Government on cultivation, manufacture and distribution of cannabis entered into force and now authorises bulk exports of medical cannabis (subject to requisite permits), whereas previously only single­dosage medical cannabis exports were allowed. The executive order is available here (DA) and a related article here FRANCE – Health Agency alerts epileptic patients on the risks related to the use of (unauthorised) cannabidiol (CBD) products sold online On 22 January 2019, the National Agency for Medicines and Health Products Safety (ANSM) published an information note reminding patients suffering from epilepsy of the potential health risks related to purchasing CBD products outside the legal circuit, in particular on unauthorised websites. The ANSM information note is available here (FR) FRANCE – Health Agency’s Temporary Specialised Scientific Committee (CSST) pursues its activities regarding the authorisation of medical cannabis in France On 30 January 2019, the ANSM announced, after having endorsed the CSST’s recommendation to authorise medical cannabis, that the committee will pursue its work on the modalities of making cannabis available for therapeutic purposes in France. In a first phase, the CSST will focus on possible methods of administration, and in a second phase, on the prescription and dispensing modalities of medical cannabis. The ANSM press release is available here (FR) and the CSST meetings are available here (FR) GERMANY – Health Agency will grant first medical cannabis cultivation contract in Q2 of 2019 On 28 January 2019, The German Federal Institute for Drugs and Medical Devices (BfArM), after having received 79 bids for the cultivation of medical cannabis in Germany, announced that the contract will be awarded in the second quarter of 2019 for a total medical cannabis procurement volume of 10,400 kg over four years. Germany’s first home­grown harvest could take place in late 2020. The press release is available here (DE) and a related article here IRELAND – Medical cannabis legally prescribed for 16 patients On 19 February 2019, the Minister of Health, when questioned on the progress of medical cannabis access in Ireland answered that, inter alia, 29 licences to prescribe medical cannabis had been already granted for 16 different patients. He also indicated that clinical guidance for healthcare professionals had been drawn up but that the full operation of the Access Programme was still pending. The Minister’s written answer is available here ISRAEL – Israeli Government approves law allowing medical cannabis export On 27 January 2019, the Israeli Government approved the bill passed by Parliament on 25 December 2018, which will allow Israeli medical cannabis production to be exported worldwide. The government expects to boost the agricultural sector and generate new tax income from such
Load more

Recommended publications
  • EMCDDA Cannabis Reader
    ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document.
    [Show full text]
  • Friday, September 12
    conference 2017 IACM 9th Conference on Cannabinoids in Medicine 29-30 September 2017 Cologne, Germany PROGRAM AND ABSTRACTS Place Maritim Hotel Heumarkt 20 50667 Cologne Germany Registration Fee The registration fee is 350 Euros. Students pay a reduced fee of 150 Euros. The registration fees include daily rates (lunch for all days, coffee during the breaks) and an evening dinner on Saturday. Organizer International Association for Cannabinoid Medicines (IACM) Am Mildenweg 6 59602 Rüthen Germany Phone: +49-2952-9708571 E-mail: [email protected] Internet: http://www.cannabis-med.org SCIENTIFIC AND ORGANIZING COMMITTEE Donald Abrams Ethan Russo Franjo Grotenhermen Kirsten Mueller-Vahl Mark Ware Roger Pertwee www.cannabinoidconference2017.org 2 Sponsors We gratefully acknowledge sponsoring by: Platin Sponors Gold Sponsors 3 Sliver Sponsors Bronze Sponsors 4 GENERAL INFORMATION Simultaneous translation There will be simultaneous translation from english into german. Badges Please wear your badge at all times during the conference. You will also need to wear it for the evening dinner. Dinner of IACM partner organizations and ambassadors On Friday we will have a dinner with the IACM partner organizations and ambassadors. Conference Dinner On Saturday evening we will have our gala dinner at the conference place. IACM Awards During the conference dinner the IACM will honour six people for their major contributions to cannabinoid research and/or to the re-introduction of cannabis into modern medicine with the IACM Award. IACM General Meeting The IACM will hold its general meeting on Saturday afternoon. Poster Sessions There will be two poster sessions at the conference: Session 1: Friday 13:00 – 15:00 during and after the lunch break.
    [Show full text]
  • A Report O Drug Mark a Report on Global Illicit Drug Markets 1998-2007
    Full Report Full EUROPEAN COMMISSION EUROPEAN COMMISSION A ReportA Reporton Global on IllicitGlobal Illicit DrugA Report on Global Illicit Drug1998-2007 Markets MarketsDrug Markets 1998-2007 1998-2007 Full ReportFull Report Numéro de catalogue ISBN-13 Numéro de catalogue ISBN-13 NE-80-09-576-EN-C 978-92-79-119N45-E-80-03 9-576-EN-C 978-92-79-11945-3 A Report on Global Illicit Drugs Markets 1998-2007 Full Report Editors: Peter Reuter (RAND) and Franz Trautmann (Trimbos Institute) http://ec.europa.eu www.trimbos.nl www.rand.org/randeurope This study has been produced by the Trimbos Institute and RAND with the financial support of the Commission of the European Communities (contract JLS/2007/C4/005). The study does not necessarily reflect the opinions and views of the European Commission, nor is it bound by its conclusions. More information on the European Union and drug policy can be found on the following website: http://ec.europa.eu/justice_home/fsj/drugs/fsj_drugs_intro_en.htm Cataloguing data can be found at the end of this publication. ISBN-13: 978-92-79-11945-3 © European Communities, 2009 Acknowledgements - A Report on Global Illicit Drugs Markets 1998-2007 Acknowledgements The authors would like to thank all people who contributed to this study. We owe a large debt to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in Lisbon for the relevant input and support we received on many issues. The EMCDDA proved to be a particularly valuable source of information and expertise for our purposes. We want to express special thanks to Paul Griffiths, Brendan Hughes, Rosemary de Sousa and Frank Zobel who provided high quality information, data and advice throughout the project, as well as to their colleagues who contributed to specific sections in this report.
    [Show full text]
  • Legal Penalty for Consuming Cannabis in Morocco
    Legal Penalty For Consuming Cannabis In Morocco herIs Mischa coracle heavy fiftieth or evangelized exogenous andafter practise cup-tied tiresomely. Garvey inlace Maury so noddingly?character senatorially. Incog and rhombic Artie jump Download Legal Penalty For Consuming Cannabis In Morocco pdf. Download Legal Penalty For gasesConsuming that is Cannabis produced In nationwide, Morocco doc. and Meant drug for major any cannabisdefinition legalof cannabis cannabis is it,morocco which the and offense? emit harmful usualCharged penalty with legalfor cannabis penalty moroccofor cannabis to learn in morocco how are and some conditions states? Unlessand politics there in. was Registered the legal inpenalty the containsfor cannabis the law.morocco Vape and or buyingshe also it legalwidely penalty tolerated consuming but uruguay cannabis is a plant morocco produces and start poisonous here are and thancommitting the legal a firearm penalty and for consumingsprinkling and cannabis other similar in the cannabisnotice and consumption consumption. are Psychotropic conservative substances when you cannabislike to clearly tolerance mark anyvaries business according to cannabis? to its effects Hands of the of differencethe usual penaltybetween cannabis morocco in and possession conditions of anotherand a dispensary. private and Refrained targeted ifads user are is there. legal forLegislative consuming session cannabis in the in usual a reality penalty in private for consuming parties or cannabis legalizationmorocco and of she larger suffers amounts from ofnative letters and may driving? not be. Tunisians Bitcoin accepted have legal by penalty the usual consuming penalty for thatconsuming people cannabiswalking down in michigan? and use Differsor a website. in your Did cannabis than traditional legal for consuminguse legal penalty in morocco for consuming to a callback court.cannabis Cactus outside in morocco of penalties.
    [Show full text]
  • A STUDY of CANNABIS SOCIAL CLUBS in BELGIUM Insights Into the Supply Model, the Movement, and Its Key Actors
    A STUDY OF CANNABIS SOCIAL CLUBS IN BELGIUM Insights into the supply model, the movement, and its key actors Mafalda Pardal Supervisors: Prof. Dr. Tom Decorte, Prof. Dr. Letizia Paoli (KU Leuven) Dissertation submitted to obtain the academic degree Doctor (Ph.D.) in Criminology Academic year: 2017 - 2018 A STUDY OF CANNABIS SOCIAL CLUBS IN BELGIUM Insights into the supply model, the movement, and its key actors Mafalda Pardal Dissertation submitted to obtain the academic degree Doctor (Ph.D.) in Criminology Supervisors: Prof. dr. Tom Decorte Prof. dr. Letizia Paoli Doctoral Guidance Committee: Prof. dr. Freya Vander Laenen Prof. dr. Beau Kilmer Department of Criminology, Criminal Law and Social Law Ghent University, Belgium Academic year 2017-2018 Acknowledgments Acknowledgments I first learned about Cannabis Social Clubs (CSCs) in 2013 while conducting research at RAND Europe. I was intrigued by both the idea of this cooperative-like, grassroots model of supply for cannabis and by the lack of visibility of the model in the scholarly and policy debates about potential scenarios for cannabis legalization. Five years on, I am very grateful to have had the opportunity to deepen my understanding of the model, and I am deeply indebted to all the Belgian Cannabis Social Club representatives, cannabis growers, members, and all other individuals who have allowed me to enter the Belgian CSC field and tolerated my many questions during the past three years, often in very trying circumstances. Thank you for your trust. It has been a privilege to work under the supervision of Prof. Dr. Tom Decorte and Prof. Dr.
    [Show full text]
  • Assessing the Economic Consequences of Two Cannabis Policy Options
    Assessing the economic consequences of two cannabis policy options Marian Shanahan, BA (Hons), MA (Econ) A thesis submitted in accordance with the requirements for admission to the degree of Doctor of Philosophy Drug Policy Modelling Program National Drug and Alcohol Research Centre School of Public Health and Community Medicine Faculty of Medicine, University of New South Wales Sydney, Australia March 2011 ii DECLARATION OF ORIGINALITY ORIGINALITY STATEMENT ‘I hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at UNSW or any other educational institution, except where due acknowledgement is made in the thesis. Any contribution made to the research by others, with whom I have worked at UNSW or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project's design and conception or in style, presentation and linguistic expression is acknowledged.’ Signed …………………………………………….............. Date …………………………………………….............. iii COPYRIGHT STATEMENT ‘I hereby grant the University of New South Wales or its agents the right to archive and to make available my thesis or dissertation in the whole or part in the University libraries in all forms of media, now or here after known, subject to the provisions of the Copyright Act 1968. I retain all proprietary rights, such as patent rights. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation.
    [Show full text]
  • The European Cannabis Reporttm
    The European Cannabis Report TM July 2018 3rd Edition TM The European Cannabis Report | Table of Contents 2 3rd Edition Table of Contents Introduction 6 Lead Sponsor Foreword 7 Executive Summary 9 An Introduction to Medical Cannabis 10 Market Size 12 Market Overview Methodology Medical Recreational Industrial Legislation 15 Overview Medical Recreational Industrial The Process of Legal Reform Regulation 20 Overview The United Nations Medical Cannabis Programs Cannabis Agencies Healthcare 22 Potential Qualifying Conditions Healthcare Analysis Commercial Opportunities 23 Corporate Social Responsibility 25 Key Countries 28 Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice. © 2018 PP Intelligence LTD. TM The European Cannabis Report | Table of Contents 3 3rd Edition Table of Contents Germany 29 Czech Republic 54 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel 6. European Panel Spain 35 France 59 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel 6. European Panel The Netherlands 40 Ireland 64 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6.
    [Show full text]
  • Global Cannabis Commission
    Acknowledgements We thank each of the following, who provided help or advice on specific points: Laurence Helfer, Les Iversen, Martin Jelsma, Shekhar Saxena, and Ambros Uchtenhagen. Particular thanks are due to Louisa Degenhardt for graciously allowing us to draw on her collaborative work with Wayne Hall. Wim Scholten and Bob Keizer provided useful advice at a Beckley Foundation meeting on the project. We also thank each of the following, who provided research or information assistance: Jude Gittins, Jonny Hazell, and Katherine Rudzinski; and Sarah Yeates for assistance in locating the literature on the health effects of cannabis and in formatting the chapter on the health effects of cannabis. Thanks also to Maggie Halls for her assistance in locating reference material for chapters on the range of reforms and their effects. The authors would like to give special thanks and appreciation to Amanda Feilding, the founder and director of the Beckley Foundation and our convenor. The report on which this book is based was Amanda’s idea in the first place, and she has been instrumental in bringing it into being, patient and helpful with suggestions, and gracious and hospitable throughout the process. i Table of Contents 4 FOREWORD 6 PREFACE 10 ACKNOWLEDGEMENTS PART I: CANNABIS POLICY: MOVING BEYOND STALEMATE 11 CHAPTER 1. INTRODUCTION 24 CHAPTER 2. THE HEALTH AND PSYCHOLOGICAL EFFECTS OF CANNABIS USE 61 ANNEX : HEALTH ADVICE ON CANNABIS USE 63 CHAPTER 3. THE CANNABIS PROHIBITION REGIME: PATTERNS OF USE, MARKETS AND POLICIES 95 CHAPTER 4. THE RANGE OF REFORMS WITHIN THE SYSTEM: SOFTENING THE PROHIBITION 130 CHAPTER 5.
    [Show full text]
  • Cannabis Policy and Legislation in the Nordic Countries
    Cannabis policy and legislation in the Nordic countries A report on the control of cannabis use and possession in the Nordic legal systems Cannabis policy and legislation in the Nordic countries A report on the control of cannabis use and possession in the Nordic legal systems Published by Nordic Welfare Centre © 2019 Project manager: Yaira Obstbaum Authors: Susanne Egnell, Emma Villman, Yaira Obstbaum Responsible publisher: Eva Franzén ISBN: 978-91-88213-38-9 Nordic Welfare Centre Box 1073, SE-101 39 Stockholm Visiting Adress: Drottninggatan 30 Phone: +46 8 545 536 00 [email protected] Nordic Welfare Centre c/o Folkhälsan FI-00250 Helsinki Visiting Adress: Topeliusgatan 20 Phone: +358 20 741 08 80 [email protected] The report can be downloaded at nordicwelfare.org/en/publikationer 2 Preface How do the Nordic countries control cannabis use in their legal systems? How do the Nordic legal systems see cannabis as a drug in 2018, and how does this affect the cannabis user? This report looks at the similarities and differences in legisla- tion and the ways in which the law is enacted in legal practice, police work, and many other arenas. While the Nordic countries have relatively similar criminal policies as a whole, there are some striking differences in their dealing with drugs such as cannabis. We therefore survey the legislative differences and similarities in this five-country report in close detail. The country profiles zoom in on the legal control of cannabis on the basis of a large body of secondary material, academic literature, and reports as well as data from Nordic statistical bureaus.
    [Show full text]
  • EMCDDA Insights: Cannabis Production and Markets in Europe
    ISSN 1606-1683 ISSN TD -XD -12- 012- EN - C productionCannabis and markets Europe in About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The EMCDDA’s Insights are volumes conveying the findings of study and research on topical issues in the drugs field. EMCDDA INSIGHTS EMCDDA Price (excluding VAT) in Luxembourg: EUR 15 INSIGHTS Cannabis production and markets in Europe 12 12 How to obtain EU publications Free publications: • via EU Bookshop (http://bookshop.europa.eu); • at the European Union’s representations or delegations. You can obtain their contact details on the Internet (http://ec.europa.eu) or by sending a fax to +352 2929-42758. Priced publications: • via EU Bookshop (http://bookshop.europa.eu). Priced subscriptions (e.g. annual series of the Official Journal of the European Union and reports of cases before the Court of Justice of the European Union): • via one of the sales agents of the Publications Office of the European Union (http://publications.europa.eu/others/agents/index_en.htm). EMCDDA INSIGHTS Cannabis production and markets in Europe 12 Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright.
    [Show full text]
  • Cannabis: the Rise and Fall of ‘A Most Valuable Medicine’
    Cannabis: The rise and fall of ‘a most valuable medicine’. 1 Cannabis: The rise and fall of ‘a most valuable medicine’. An analysis of medical use and prohibition of the cannabis plant in Modern England. Suzannah Eliza Shimwell, B.A. Submitted in partial fulfilment of the requirements for the degree of MASTER of HISTORY UNIVERSITY OF EAST ANGLIA May 2005 2 Table of Contents List of appendices p2 Acknowledgements p3 Introduction p4-6 Part One: Chapter 1: The History of Medical Usage of Cannabis p7-11 Cannabis and the Empire p11-17 Chapter 2: Medical Uses In Nineteenth And Twentieth Century England p18-26 Cannabis and Insanity p27-35 Cannabis and the Laity p35-37 Some Conclusions p38-39 Part Two: Chapter 3: Decline of Cannabis p40-63 Chapter 4: The Logistics Of Prohibition p64-87 The Success of Prohibition p87-88 Conclusion p89-91 Appendices p92-96 Bibliography p97-113 3 List of Appendices Appendix I: List of uses of cannabis in 1899 Appendix II: Table of figures relating to drug offences Appendix III: Some examples of prohibition failure 4 Acknowledgements Special thanks are due to Dr Steven Cherry, for his invaluable support and guidance. Thanks should be given to all those in the History Department at the University of East Anglia who have supported me with my research. Thanks are also due to all of the libraries that assisted me with my research, including the helpful staff at the British Library and those at the University of East Anglia Library. 5 Introduction The quote used in the title is from an article by J.
    [Show full text]